TOVX נכסי החברה Synthetic Biologics

Theriva Biologics, Inc. (TOVX) is implementing AI models and automated bioreactors to optimize drug development by eliminating human error. The business relies on the development of oncolytic viruses, anticipating the success of VCN-01 and a potential merger. This chart of total asset price action is 39.95. Meanwhile, the company adheres to basic environmental standards, as current laboratory tests have virtually no impact on the environment.

Total assets represent the aggregate value of the organization's resources, which is reconstructed via a reverse ROA calculation to identify abnormal deviations and eliminate speculative risks. An analysis of total assets allows for an assessment of the real value of the material base of Theriva Biologics (TOVX), reflecting the efficiency of capital allocation between oncolytic virus development and microbiome protection to minimize scientific risks in oncology.